日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

p53: from understanding its structure to advances in therapeutic targeting

p53:从理解其结构到治疗靶向治疗的进展

Wang, Wenhua; Liu, Xia; Liu, Hengqi; Abolhassani, Hassan; Yan, Han; Zhang, Huilai; Wang, Xianhuo

Spatial omics study reveals molecular-cellular dynamics of tumor ecosystem in esophageal squamous-cell carcinoma initiation and progression.

空间组学研究揭示了食管鳞状细胞癌发生发展过程中肿瘤生态系统的分子细胞动力学。

Liu Zhao, Zhou Wenhao, Li Lei, Song Congcong, Yue Meng, Lv Huilai, Li Zhenhua, Zhang Minghao, Li Na, Wang Jiaqian, Zhao Lianmei, Luo Haitao, Tian Ziqiang

Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study

新辅助化疗联合免疫治疗后食管鳞状细胞癌的辅助免疫治疗:一项多中心真实世界研究

Chen, Chunji; Tian, Ziqiang; Lin, Jiangbo; Leng, Xuefeng; Shen, Jianfei; Zhao, Jinbo; Lv, Huilai; Wang, Changchun; Mei, Xinyu; Han, Yongtao; Wang, Qifeng; Lv, Jiahua; Chen, Hainan; Yan, Xiaolong; Liu, Zhichao; Zhang, Zhengyang; Zhong, Qihong; Jiang, Youhua; Xu, Liwei; Li, Xiaoyang; Qian, Dong; Ma, Dehua; Ye, Minhua; Wang, Chunguo; Wang, Zimin; Li, Zhigang; Guo, Xufeng

Efficacy and safety of secondary induction radiotherapy in locally advanced resectable esophageal squamous cell carcinoma with poor responses to neoadjuvant immunochemotherapy: a retrospective study

新辅助免疫化疗反应不佳的局部晚期可切除食管鳞状细胞癌二次诱导放疗的疗效和安全性:一项回顾性研究

Lv, Huilai; Zhang, Ping; Dai, Liang; Ding, Weilu; Xie, Songping; Jiang, Hongjing; Duan, Xiaofeng; Chen, Ke-Neng; Tian, Ziqiang

Spatial profiling uncovers multicellular dynamics in early relapse of hepatitis B virus-associated follicular lymphoma

空间分析揭示乙型肝炎病毒相关滤泡性淋巴瘤早期复发中的多细胞动力学

Deng, Yuwei; Zhang, Qingyuan; Jia, Zhenyuan; Thorne, Rick F; Zhang, Huilai; Liu, Xuhui; Ma, Jianli

Oxygen-releasing seed coating enhances yield and resource use efficiency in direct-seeded rice

氧气释放型种皮可提高直播稻的产量和资源利用效率

Shi, Yuanqing; Yin, Huilai; Zhu, Yuemei; Liu, Ruhongji; Chen, Qiqi; Xie, Hongkun; Liu, Binbin; Cheng, Qingyue; Shu, Chuanhai; Liu, Ning; Ma, Jun; Sun, Yongjian; Li, Na; Yang, Zhiyuan

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study

大型临床试验中患者报告结局(PRO)与临床医生报告的不良事件:POLARIX 3期研究结果

Thompson, Carrie; Trněný, Marek; Morschhauser, Franck; Salles, Gilles; Reagan, Patrick M; Hertzberg, Mark; Zhang, Huilai; Thieblemont, Catherine; Hu, Bei; Fonseca, Gustavo; Kim, Won Seog; Martelli, Maurizio; Mehta, Amitkumar; Singh, Avrita; Yan, Mark; Hirata, Jamie; Sugidono, Matthew; Lee, Calvin; Sharman, Jeff P; Mehta-Shah, Neha; Flowers, Christopher R; Tilly, Hervé; Chua, Neil; Casasnovas, René-Olivier; Miall, Fiona; Kim, Tae Min; Tsai, Xavier Cheng-Hong; Nasta, Sunita; Lee, Seung Tae; Friedberg, Jonathan W

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

莫苏妥珠单抗联合波拉妥珠单抗治疗不适合移植的难治性/复发性大B细胞淋巴瘤:III期SUNMO试验的主要结果

Budde, Lihua E; Zhang, Huilai; Kim, Won-Seog; Maruyama, Dai; Rego, Eduardo M; Norasetthada, Lalita; Hong, Huangming; Ozcan, Muhit; Jeon, Young-Woo; Leão Cordeiro de Farias, Danielle; Fogliatto, Laura Maria; Pavlovsky, Astrid; Goto, Hideki; Olszewski, Adam J; Shah, Nikesh; Hu, Bei; Yin, Shen; Wu, Hao; To, Iris; Ead, Wahib S; Ashby, Joan; Janousek, Martin; Pham, Song; Wang, Jue; Kwan, Antonia; Batlevi, Connie L; Wei, Michael C; Westin, Jason

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

作者更正:Odronextamab 单药治疗复发/难治性弥漫性大 B 细胞淋巴瘤患者:ELM-2 II 期试验的主要疗效和安全性分析

Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Odronextamab单药治疗复发/难治性弥漫性大B细胞淋巴瘤患者:ELM-2 II期试验的主要疗效和安全性分析

Kim, Won Seog; Kim, Tae Min; Cho, Seok-Goo; Jarque, Isidro; Iskierka-Jażdżewska, Elżbieta; Poon, Li Mei; Prince, H Miles; Zhang, Huilai; Cao, Junning; Zhang, Mingzhi; Tessoulin, Benoît; Oh, Sung Yong; Lim, Francesca; Carpio, Cecilia; Tan, Tran-Der; Ayyappan, Sabarish; Gutierrez, Antonio; Cai, Jingxian; Ufkin, Melanie; Shariff, Saleem; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Walewski, Jan